©2025 Stanford Medicine
A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung Fibrosis
Not Recruiting
Trial ID: NCT04308681
Purpose
The purpose of this study is to provide an initial evaluation of the effectiveness of BMS-986278 in participants with lung fibrosis, to demonstrate the safety of BMS-986278, and provide information on the drug levels of BMS-986278 in these participants.
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2 Study of the Efficacy and the Safety and Tolerability of BMS-986278 in Participants With Pulmonary Fibrosis
Stanford Investigator(s)
Rishi Raj
Clinical Professor, Medicine - Pulmonary, Allergy & Critical Care Medicine
Eligibility
Inclusion Criteria:
For the idiopathic pulmonary fibrosis (IPF) Cohort
* Diagnosis of IPF within 7 years of screening
* Female and males ≥ 40 years of age
For the progressive fibrotic interstitial lung disease (PF-ILD) Cohort
* Evidence of progressive ILD within the 24 months before screening
* Female and male ≥ 21 years of age.
Exclusion Criteria:
* Women of childbearing potential (WOCBP)
* Active Smokers
* Current malignancy or previous malignancy up to 5 years prior to screening
* History of allergy to BMS-986278 or related compounds
Other protocol-defined inclusion/exclusion criteria apply
Intervention(s):
other: BMS-986278 Placebo
drug: BMS-986278
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Rishi Raj, Site 0043
650-736-8083